During pneumococcal pneumonia, antibacterial defense requires the orchestrated expression of innate immunity mediators, initiated by alveolar macrophages and dependent on transcription driven by nuclear factor κB (NF-κB). Such immune pressure may select for pneumococci, which avoid or subvert macrophage NF-κB activation. Analyzing pneumococci collected from children in Massachusetts, we found that the activation of macrophage NF-κB by Streptococcus pneumoniae is highly diverse, with a preponderance of low NF-κB activators that associate particularly with complicated pneumonia. Low NF-κB activators cause more severe lung infections in mice, and they drive macrophages toward an alternate and detrimental cell fate of necroptosis. Both outcomes can be reversed by activation of macrophages with pneumococci that are high NF-κB activators. These results suggest that low NF-κB activation is a virulence property of pneumococci and that the appropriate activation of macrophages, including NF-κB, may hold promise as an adjunct therapeutic avenue for pneumococcal pneumonia.
Globally, pneumonia ranks consistently as the greatest or second greatest burden of disease across multiple World Health Organization assessments spanning decades [1] . For children, it is the most common cause of death worldwide and the most common reason for hospitalization in the United States [1] [2] [3] . It is an even greater problem for the elderly, with higher pneumonia risk compared with any earlier age and with the greatest risk of death compared with other leading reasons for seniors to be hospitalized [4] . The bacterial species most commonly causing pneumonia for both children and the aged is Streptococcus pneumoniae, also known as pneumococcus [5, 6] . This Gram-positive pathobiont colonizes the nasopharynx of most people during the first years of life. Colonization can be asymptomatic and persist for months without any serious consequence. However, if the bacteria grow in the lower respiratory tract, then pneumonia ensues and infection can be severe. In the lung, the alveolar macrophages are the first leukocytes to encounter pathogens, and they play key roles in driving the innate immune response [7] . The induction of many innate immunity mediators depends on the transcription factor nuclear factor κB (NF-κB) during pneumonia [8, 9] . During pneumococcal pneumonia, activation of NF-κB in alveolar macrophages is pivotal for expression of essential cytokines such as tumor necrosis factor (TNF) and interleukin 1 (IL-1), and its loss leads to failures of antibacterial lung defense [9] [10] [11] . Because pneumococci grow better in the lungs of mice in which NF-κB is defective in macrophages [10] , pneumococci that avoid or subvert macrophage NF-κB may more likely cause severe respiratory infection. We endeavored to test whether pneumococci vary in macrophage NF-κB activation and, if so, whether those triggering less macrophage NF-κB are more virulent in the lungs.
Medical Campus. Two additional laboratory strains were included, 6303 (from the ATCC) and EF3030 (kindly provided by Dr Marc Lipsitch, Harvard School of Public Health). Bacteria were cultured overnight on sheep blood agar plates in a humidified 37°C 5% carbon dioxide incubator immediately before use in experiments.
Mice
Mice lacking RelA in myeloid cells were generated by crossing LysM-Cre mice [14] with Rela-floxed mice [15] , as previously described [10] . C57BL/6 mice were purchased from Jackson Labs. Mice were aged 6-12 weeks and included both sexes. Animal experiments were approved by the Institutional Animal Care and Use Committee of Boston University.
Cell Culture Infection
NF-κB reporter cells were created by stably infecting RAW264.7 cells with a lentivirus containing firefly luciferase driven by a minimal promoter and 4 tandem NF-κB sites [16] . For primary cells, alveolar macrophages were collected by bronchoalveolar lavage from C57BL/6 mouse lungs. To stimulate cells, the medium was removed, and fresh serum-free and antibiotic-free media containing designated isolates of live S. pneumoniae at 10 7 colony-forming units (CFUs)/well (unless otherwise specified) were added for up to 2 hours at 37°C and 5% carbon dioxide. Some experiments included 30 μM of BAY 11-7082 (Santa Cruz Biotechnology).
Pneumonia Model
Mice were anesthetized by intraperitoneal ketamine (50 mg/ kg) and xylazine (5mg/kg). After the trachea was surgically exposed, an angiocatheter was inserted and directed to the left bronchus, through which 50-μL volumes containing S. pneumoniae in sterile saline were instilled [9] . At indicated times, mice were killed, and lungs were lavaged or homogenized in sterile distilled water containing protease inhibitors (Roche no. 11849300). Homogenates were serially diluted for CFU analyses. Cytokine concentrations [17] were measured using TNF-α and CXCL2 Duoset enzyme-linked immunosorbent assay (ELISA) antibodies (R&D Systems).
Nuclear Translocation of NF-κB RelA
RAW264.7 cells cultured in 35-mm glass bottom dishes were washed with phosphate-buffered saline and cultured with S. pneumoniae in serum-free, antibiotic-free, and phenol redfree Dulbecco's modified Eagle's medium for 2 hours, after which they were washed and fixed in 4% paraformaldehyde. For primary alveolar macrophages, cells were lavaged from infected and uninfected mice, cytocentrifuged onto slides, and fixed in 4% paraformaldehyde. NF-κB RelA was detected using a primary antibody (Santa Cruz no. sc-372) followed by a fluorescein-conjugated secondary antibody (Life Technologies no. A-11008). Additional stains included phalloidin (Biotium no. 00043-T) for actin and 4',6-diamidino-2-phenylindole (DAPI) for nuclei.
Confocal Microscopy
Images were obtained with a Zeiss LSM 710-Live Duo scan microscope. Cells were stained with Hoechst (Life Technologies no. 33342) for chromatin labeling, Cell Mask Green (Life Technologies no. C37608) for plasma membrane, CellROX Deep Red (Life Technologies no. C10422) for reactive oxygen species, and/or NucRed Dead 647 Ready Probes Reagent (Molecular Probes no. R37113) for plasma membrane permeability, as indicated. In select experiments, cells were pretreated with Necrostatin-1 (Sigma-Aldrich) at 10 -4 M for 90 minutes before infection. Oncosis was defined by swelling of the cytoplasm relative to nucleus, with rounded outer regions or fully spherical cells, quantified by an investigator blinded to experimental group.
Screening for NF-κB Activation
NF-κB reporter cells were washed with phosphate-buffered saline and lysed using Passive Lysis Buffer (Promega no. E1941). Luminescence was measured using a Luciferase Assay Protocol (Promega no. E1501) on a Veritas Microplate Luminometer. Parallel wells with vehicle (assay media alone) or lipopolysaccharide (LPS) from E. coli (InvivoGen no. tlrl-3pelps) at 10 ng/ mL were included as negative and positive controls, respectively. Results from pneumococcus were expressed relative to the parallel LPS wells within the same plate for each experiment.
Statistical Analysis
Data were presented in bar graphs as mean ± standard error or in box-whisker plots showing median and quartiles. Sets containing 2 groups of data were compared using Mann-Whitney U test, and sets of >3 groups of data were analyzed using analysis of variance (ANOVA). Differences were considered statistically significant if P < .05.
RESULTS

Differential Activation of Macrophage NF-κB by Pneumococci With
Known Variation in Virulence
We compared NF-κB activation by pneumococcal isolates with consistent differences in infection severity during mouse models of pneumonia. The 6303 isolate causes lethal pneumonia and bacteremia after even low-dose infections [9, 11, 18] . The EF3030 strain causes self-limiting infections and no bacteremia in mice, even with millions of CFUs in the lungs [9, 11, 19] . Alveolar macrophages from mice infected with EF3030 showed greater RelA nuclear translocation compared with those from mice infected with 6303 ( Figure 1A) . A more reductionist system, macrophage-like RAW264.7 cells stimulated in vitro with live pneumococcus, similarly showed more pronounced NF-κB RelA translocation from EF3030 than from 6303 ( Figure 1B) .
To quantify NF-κB activity, we generated macrophage NF-κB reporter cells by transducing RAW264.7 cells with a lentiviral vector containing a firefly luciferase transgene driven by tandem NF-κB consensus binding sites [16] and established stable clonal cell lines. Luciferase induction was expressed relative to LPS positive control wells. Consistently, the less virulent EF3030 isolate induced greater luminescence than the more virulent 6303 strain throughout the dose range and across 5 different clonal cell lines ( Figure 1C ). The dose-response curves revealed 10 7 CFUs/mL or a multiplicity-of-infection of 10:1 to be well suited to the assay system, which was used for further studies. At this concentration, multiple independent experiments demonstrated that 6303 stimulated significantly less NF-κB activation than EF3030 ( Figure 1D ). These results using laboratory isolates of pneumococcus with known differences in virulence in mouse models support our hypothesis that low NF-κB activation is characteristic of more severe pneumococcal infections. In addition, they establish an assay system that can be used for screening NF-κB activation by "real-world" isolates of pneumococcus collected from human volunteers and patients.
Screening of Community Isolates for NF-κB Activation
We generated a bio-bank of pneumococcal isolates from children in Massachusetts, useful for analyzing pneumococcal variations that influence mammalian biology and human health. Isolates derived from patients with invasive pneumococcal disease (IPD) and volunteers (carrying pneumococcus but without disease) were screened using the macrophage bioassay to ascertain macrophage NF-κB activation levels, revealing a wide variation in NF-κB triggered by the different isolates ( Figure 2A ). NF-κB activation did not follow a normal distribution (P < .02, Shapiro-Wilk test); rather than a bell-shaped curve, the distribution was skewed leftward (skewness = 0.39) and flattened (kurtosis = −0.41). Thus, pneumococci vary markedly in their activation of macrophage NF-κB, and more isolates than expected are low activators. Perhaps the best recognized determinant of virulence for pneumococcus is the capsular Figure 1 . Divergent NF-κB activation in alveolar macrophages by strains of Streptococcus pneumoniae with different virulence characteristics. A, Alveolar macrophages were collected by bronchoalveolar lavage 2 hours after intratracheal instillation of EF3030 or 6303 to C57BL/6 mice so that NF-κB RelA could be revealed using immunohistochemistry. Scale bar: 10 μm. Two independent experiments, 4-6 mice/group. DAPI (4',6-diamidino-2-phenylindole) was used to definitively discriminate nuclei, but that channel was not included in the figure to better show the RelA signal throughout the cell. B, After 2 hours of culture with EF3030 or 6303, RelA in RAW264.7 cells was detected by immunofluorescence using confocal microscopy. Scale bar: 10 μm. Two independent experiments showed the same result. DAPI was used to definitively discriminate nuclei, but that channel was not included in the figure to better show the RelA signal throughout the cell. C, RAW264.7 cells were stably transduced with an NF-κB-driven luciferase reporter transgene so that 5 clonal lines could be established and tested. Cells were cultured for 2 hours with EF3030 or 6303 at designated doses. Luciferase in cell lysates was expressed as a percentage of lipopolysaccharide-induced responses from parallel wells. D, Significantly less induction of NF-κB-mediated gene expression by 6303 compared with EF3030. * P < .05 (Mann-Whitney U test) from n = 3 independent experiments. Abbreviations: AMs, alveolar macrophages; LPS, lipopolysaccharide; RAW, RAW264.7.
polysaccharides separating them into >90 different serotypes [20] [21] [22] [23] . We observed significant differences among serotypes (P < .05, 1-way ANOVA), but as much or more variation was observed within a given serotype as among them ( Figure 2B ). Thus, there is an association between NF-κB and serotype, but it is weak. We conclude that serotype-related capsular polysaccharide heterogeneity is likely one of multiple features that influence macrophage NF-κB activation, causing the pronounced variation in macrophage NF-κB activation across the pneumococcal population.
Low Macrophage NF-κB Activation as a Facilitator of Infection During
Pneumonia
Because macrophage NF-κB is pivotal to lung defense against pneumococcus [11, 18, 20] , we evaluated the relationship between degree of macrophage NF-κB activation and the severity of pneumococcal infection. When carriage isolates collected from asymptomatic children were compared with invasive isolates from those with IPD, NF-κB activation was significantly different between groups (carriage isolates: median = 50.0, 95% confidence interval [CI] = 40.7-53.9; IPD: median = 27.0, 95% CI = 24.3-39.8; P = .003, Mann Whitney U test). Pneumococci that were collected from pleural fluids were necessarily from patients with pneumonia complicated by empyema. Pneumococci from blood or CSF were from patients with IPD but not necessarily pneumonia. Samples from the nasopharynx came from children without pneumococcal disease. The screen results revealed wide variation in degree of NF-κB activation among pneumococcal isolates found in the nasopharynx, blood, or CSF ( Figure 2C ). Isolates collected from the pleural fluid of empyema patients showed significantly lower NF-κB activation in comparison with other sites ( Figure 2C ). These data suggest that low NF-κB activation may be especially critical for pneumococcal survival in some settings, including but not necessarily limited to patients with complicated pneumonia.
To directly compare the abilities of high and low NF-κB-activating isolates of pneumococcus to survive within the lungs, we turned to an animal model. We compared isolates matched for serotype but differing in NF-κB activation for 2 different serotypes, 19A and 19F, in mice with lobar pneumonia. Local cytokine production was measured using ELISA on lung homogenates, focusing on TNF-α and CXCL2 because both are macrophage derived and NF-κB dependent during pneumococcal pneumonia [10] . For both serotypes 19A ( Figure 3A ) and 19F (Figures 3B), those isolates that activated less macrophage NF-κB in the screening assay triggered less in vivo expression of macrophage-derived cytokines in infected lungs. For both serotypes, the isolates that activated more macrophage NF-κB and were stronger inducers of macrophagederived cytokines were more readily eliminated from infected mouse lungs ( Figure 3C and 3D) . These data support the concept that avoiding or subverting macrophage NF-κB activation during acute pneumonia enhances S. pneumoniae survival in the lung. Aberrant Macrophage Responses Triggered by Low NF-κB ActivatorsIf low NF-κB activity results from ineffective macrophage recognition of pneumococci, then all macrophage responses may be diminished during infection with pneumococci that are low NF-κB activators. However, pathogens can reroute cell signaling to circumvent innate immune defenses [24] , suggesting an alternative hypothesis that virulent pneumococci do not simply avoid detection but rather skew responses away from protective activities like NF-κB-mediated gene transcription and toward other outcomes instead. Confocal microscopy revealed that some macrophage responses are inversely associated with NF-κB activation, supporting the latter hypothesis. For both laboratory and clinical isolates of S. pneumoniae, the low NF-κB activators but not the high NF-κB activators caused distinct changes in macrophage morphology ( Figure 4A and 4B). Although cells responding to high NF-κB activating isolates tended to become more elongated and amoeboid compared with uninfected cell cultures, the macrophages stimulated with low NF-κB activators were strikingly different, tending instead to become larger and rounder ( Figure 4A and 4B ). In addition, for both the laboratory and the community isolates, cells stimulated with low NF-κB activator pneumococci produced more reactive oxygen species (ROS) than macrophages stimulated with high NF-κB activators ( Figure 4C and 4D) . Live cell imaging revealed that cells responded in a largely synchronous fashion throughout the culture, with ROS generation preceding the cell swelling response ( Figure 5A ). Cell lines can have idiosyncratic responses, so we examined primary alveolar macrophages from mouse lungs. When cultured with pneumococci, alveolar macrophages responded to the high NF-κB activator but not the low NF-κB activator with cellular oncosis (Figure 5B ), demonstrating that these divergent responses apply directly to the macrophages patrolling the surfaces of the lung. These data refute the hypothesis that low NF-κB activators are stealth organisms that are not recognized by macrophages. Instead, low NF-κB activators drive macrophages toward an alternate cell fate.
Necroptosis
Cell swelling and abundant ROS production are hallmarks of programmed necrosis, reflecting processes of cellular oncosis and energetic catastrophe [25] . In addition to cellular rounding, swelling of an increasingly translucent cytoplasm, and ROS abundance, cells undergoing programmed necrosis are defined by their loss of plasma membrane integrity [25] . We stimulated RAW264.7 cells with either low or high NF-κB-activator S. pneumoniae or vehicle control and measured nuclear staining from a membrane-impermeable fluorescent dye. After 2 hours of coculture, cells stimulated with low NF-κB activators showed increased levels of plasma membrane permeability, whereas cells cultured with high NF-κB-activating pneumococci did not ( Figure 6A ). Thus, low NF-κB activators increase membrane permeability in conjunction with cellular oncosis and excess ROS production, indicative of programmed necrosis. Multiple pathways of programmed necrosis can be distinguished by their underlying molecular mechanisms [25] . Necroptosis is mediated by the necrosome, including the kinase activity of RIPK1 [25] . When stimulated by low NF-κB-activating pneumococci, signs of (A and B) , 5 mice per group were killed 6 hours after infection, and tumor necrosis factor α and CXCL2 were measured using enzyme-linked immunosorbent assay in lung homogenate preparations. For bacterial burdens (A and B), 4-5 mice per group were killed 15 hours after infection, and colony-forming units (CFUs) were quantified in lung homogenate preparations. Data in all cases were collected in 2 independent experiments. Kruskal-Wallis tests were used to test for significant effects of low versus high NF-κB activation across multiple cytokines within serotypes and for CFUs across both serotypes. Asterisks (*) represent statistical significance (P < .05).
programmed necrosis, including ROS production and cellular oncosis, were inhibited by the RIPK1 inhibitor Necrostatin-1 ( Figure 6B and 6C) . Altogether, these results suggest that the altered macrophage responses elicited by low NF-κB activators reflect pneumococcal induction of programmed necrosis.
NF-κB and Programmed Necrosis
Because NF-κB activity and necroptosis are inversely correlated and prior studies show NF-κB can inhibit inflammatory cell death [8, 26 , 27], we tested whether pharmacological inhibition of NF-κB would increase necroptosis among macrophages responding to pneumococci. The BAY 11-7082 inhibitor of NF-κB was effective at preventing pneumococcal activation of NF-κB ( Figure 7A ). This inhibitor significantly increased necroptosis in RAW264.7 cells responding to a high NF-κB activator pneumococcus, as detected by cellular oncosis ( Figure 7A ). This supports the concept that pneumococcusstimulated NF-κB activity helps to prevent necroptosis in macrophages.
Preventing Necroptosis and Severe Pneumonia
These studies suggest that different pneumococci can drive macrophages toward either of 2 cell fates: (1) NF-κB-mediated gene expression, with cytokine production eliminating bacteria from the lungs, or (2) necroptosis, with less NF-κB activation and more severe infection. We designed a series of in vitro costimulation and in vivo coinfection experiments to test whether macrophage necroptosis and lung infection caused by low NF-κB activators could be reversed and improved by the presence of high NF-κB activators. Macrophage-like cells were cultured in vitro with a low NF-κB-activating pneumococcus (6303) or with that same dose of 6303 plus an equivalent dose of high NF-κB-activating pneumococcus (EF3030). Intriguingly, the presence of EF3030 prevented the morphological changes caused by 6303 ( Figure 7B ). These data demonstrate that high NF-κB activator pneumococci can stimulate pathways that overcome the deleterious necroptosis pathways elicited by the low NF-κB activator. To determine whether such protection might apply in vivo during pneumonia, we infected wild-type 07AR0013 below) . B, Low NF-κB activators caused significantly more oncosis (P < .05, 1-way ANOVA with Sidak's multiple comparisons test). C, Confocal imaging of increased reactive oxygen species (ROS) in RAW264.7 cells after 15 minutes of stimulation with low NF-κB-activating S. pneumoniae (6303 above or BMC0359C below) compared with high NF-κB activators (EF3030 above or 07AR0013 below). D, Low NF-κB activators generated significantly more ROS (P < .05, 1-way ANOVA with Sidak's multiple comparisons test). Results from n = 3 independent experiments. Scale bars: 10μm.
mice with intratracheal inoculations with low NF-κB activator S. pneumoniae strain 6303 alone or with that same dose of 6303 plus an excess of high NF-κB activator strain EF3030. Colony-forming units were enumerated in homogenates from lungs harvested 48 hours after infection. Mice that received 6303 alone experienced severe infections with bacterial burdens in the lung orders of magnitude above the infecting dose ( Figure 7C ). In contrast, the lungs of mice that received the same dose of 6303 but also an excess of EF3030 had reduced CFUs, far less than the original infecting dose ( Figure 7C ). These CFUs were exclusively 6303, based on colony morphology; EF3030 was eliminated by this time point. Thus, the presence of EF3030 enhanced host defense and elimination of 6303 from the lungs, demonstrating that a high NF-κB activator could protect in vivo against severe pneumonia caused by a necroptosis inducer. Finally, to determine whether macrophage NF-κB was essential to this pneumococcus-induced protective activity, we tested mice with targeted mutation of NF-κB RelA in myeloid cells, including alveolar macrophages [10] . In contrast with our results in wild-type mice, the presence of high NF-κB activator pneumococci did not enhance host defense against low NF-κB activator pneumococci in the lungs of mice whose alveolar macrophages lacked NF-κB RelA ( Figure 7D) . Therefore, the ability of the less virulent strain of S. pneumoniae to provide defense against the more virulent strain was entirely dependent on macrophage NF-κB. These data suggest that appropriate macrophage activation involving NF-κB RelA can enhance the elimination of an otherwise highly virulent necroptosis-inducing isolate of S. pneumoniae during lung infection.
DISCUSSION
Our studies reveal that pneumococci that are low activators of NF-κB skew alveolar macrophage responses and worsen pulmonary infections. Low NF-κB activation was associated with pneumonia complicated by empyema in children and with more severe lung infection in an animal model. The concept that subverting macrophage NF-κB activation is a virulence pathway for pneumococcus emerged from analyses of clinical isolates representing a complex and dynamic population of hosts and microbes but from a limited age range (children), geographic region (Massachusetts), and time period (approximately a decade). Pneumococci may be under different types of selective pressure in different populations, places, and times. The data collected here support the postulate that pneumococci subvert NF-κB to cause severe infection.
Pneumococci that cause disease tend to activate macrophage NF-κB less than those from asymptomatic carriage. However, there was considerable overlap between groups, with some low NF-κB activators coming from healthy subjects and some high NF-κB activators from sick patients, emphasizing that NF-κB is not the only parameter determining whether pneumococci cause clinical infection. The NF-κB activation phenotype appears genomically stable and conserved across rounds of isolation, freeze-thaw cycles, and growth in or on media. Pneumococci with such genomes may have a selective advantage in some pathophysiological settings, such as pleural effusions based on the patient data shown here. Other tissues, like the nasopharynx, blood, or CSF, may exert different selective pressures, and results do not suggest selection by NF-κB activation in those anatomic locations.
Multiple consequences of low NF-κB activation in alveolar macrophages may influence the degree of lung infection. Macrophages are unique sources for some cytokines during pneumococcal pneumonia, including TNF-α, IL-1α, IL-β, and CXCL2 [10, 28] , and these cytokines are essential to effective lung defense against bacteria [11, 29, 30] . Diminished expression of macrophage-derived cytokines due to decreased NF-κB activity likely enables the intrapulmonary survival and growth of those bacteria that are low NF-κB activators. The low NF-κB-activating isolates also elicited macrophage necroptosis. Multiple toxins from diverse bacteria can kill macrophages by necroptosis, which can be relevant to pneumonia based on mouse models of infection with Staphylococcus aureus or Serratia marcescens [31, 32] . Loss of these cells and their antimicrobial activities, in addition to decreases in NF-κB-mediated expression of cytokines, may further contribute to the enhanced survival of low NF-κB-activating pneumococci in the lungs. The pneumococcal toxin pneumolysin can induce cell death that depends on necrosome components [32] , suggesting this may be 1 determinant of whether and which pneumococci trigger necroptosis. Intracellular signaling can prevent necroptosis, Figure 6 . A necroptotic cell fate. A, Plasma membrane permeability was assessed using NucRed Dead in RAW264.7 cells cultured 2 hours with high (EF3030) or low (6303) NF κB activators. B, Cellular oncosis was assessed in CellMask-stained RAW264.7 cells cultured 2 hours with low NF-κB activator pneumococci (6303) ± Necrostatin-1. C, Cellular oncosis was assessed in CellROX-stained RAW264.7 cells cultured 15 minutes with low NF-κB activator pneumococci (6303) ± Necrostatin-1. Scale bars: 10μm. For all, * P < .05 from n = 3 independent experiments, using Mann-Whitney U tests. and the inhibition of FADD or caspase-8 under inflammatory conditions causes necroptosis [33] . It is conceivable that necroptosis-inducing pneumococci inhibit select intracellular pathways in macrophages, thereby potentiating necroptosis. The degree of NF-κB activation may itself be pivotal. Loss of NF-κB RelA leads to programmed cell death in response to inflammatory cytokines such as TNF-α and IFN-γ [8, 26, 27] , and a pharmacological inhibitor of NF-κB was sufficient to increase necroptosis in our assays. Thus, diminished NF-κB activity in the presence of other pneumococcus-induced inflammatory pathways may cause necroptosis.
Rerouting macrophage signaling away from the detrimental fate may be beneficial for fighting pneumococcal pneumonia. In our studies, the less virulent high NF-κB activators counteracted the adverse outcomes caused by low NF-κB activators, preventing macrophage necroptosis and enhancing antibacterial lung defense, suggesting the appropriate stimulation of macrophages can neutralize or reverse the pathophysiological signaling elicited by virulent pneumococci. Mutation of RelA in the myeloid lineage inhibited this protection, indicating that NF-κB activation in macrophages is essential to the lungprotective effects elicited by less virulent pneumococci. Bacteria would not be a promising approach for treating pneumonia, but these results are provocative for indicating that activating macrophage pathways can be powerfully protective during pneumococcal pneumonia. These pathways include (but may not be limited to) NF-κB-mediated gene transcription, providing direction for development of adjunct immunostimulatory therapies for pneumonia, particularly that caused by antibioticresistant bacteria [34, 35] . Figure 7 . NF-κB activation determines necroptosis and severe pneumonia. A, RAW264.7 cells were cultured 2 hours with vehicle alone, a high NF-κB activator isolate of pneumococcus (EF3030), or with EF3030 plus BAY 11-7082. NF-κB activation was quantified using a NF-κB-luciferase reporter system (data shown as thousands of relative light units), and cellular oncosis was quantified using CellMask and confocal microscopy (data shown as percentage of cells showing features of oncosis). P < .05 by 2-way analysis of variance (ANOVA) from n = 3 independent experiments for both assays. B, Cellular oncosis was quantified in CellMask-stained RAW264.7 cells cultured 2 hours with low NF-κB activator pneumococci (6303) or equal concentrations of low NF-κB activator pneumococci (6303) plus high NF-κB activator pneumococci (EF3030). P < .05 by 1-way ANOVA from n = 3 independent experiments. C, C57BL/6 mice received intratracheal instillations of either 10 5 colony-forming units (CFUs) of low NF-κB activator pneumococci (6303) or 10 5 CFUs of low NF-κB activator pneumococci (6303) plus 10 7 CFUs of high NF-κB activator pneumococci (EF3030), and CFUs/lung were enumerated after 48 hours. D, Experiments as in C were repeated in LysM-Cre/Rela-floxed mice (RelA MacΔ ) in which RelA is mutated in macrophages. For in vivo studies, n = 6-9 mice per group collected in multiple independent experiments. P < .05 by Mann-Whitney U tests.
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